Walvax Biotechnology Co Ltd
SZSE:300142
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.9
23.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Gross Margin
Walvax Biotechnology Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | CN |
| Market Cap | 20.5B CNY |
| Gross Margin |
81%
|
| Country | FR |
| Market Cap | 6T USD |
| Gross Margin |
0%
|
| Country | US |
| Market Cap | 311.8B USD |
| Gross Margin |
67%
|
| Country | US |
| Market Cap | 140.7B USD |
| Gross Margin |
60%
|
| Country | US |
| Market Cap | 115.7B USD |
| Gross Margin |
78%
|
| Country | US |
| Market Cap | 102.7B USD |
| Gross Margin |
86%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Gross Margin |
76%
|
| Country | AU |
| Market Cap | 134.4B AUD |
| Gross Margin |
52%
|
| Country | US |
| Market Cap | 78B USD |
| Gross Margin |
87%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Gross Margin |
75%
|
| Country | NL |
| Market Cap | 36B EUR |
| Gross Margin |
89%
|
Walvax Biotechnology Co Ltd
Glance View
Nestled within China's burgeoning biotechnology sector, Walvax Biotechnology Co Ltd has emerged as a formidable player in the field of vaccine development and production. Founded in 2001, the company has adeptly positioned itself to address the pressing health care needs in China and beyond. As a modern biopharmaceutical manufacturer, Walvax combines cutting-edge research with robust manufacturing capabilities, focusing primarily on the development of human vaccines. Its portfolio encompasses vaccines for a variety of infectious diseases, including those that target influenza, pneumonia, and rotavirus, allowing it to carve out a significant niche in the industry. By leveraging partnerships with global research institutions and investing heavily in R&D, Walvax continually enhances its product offerings, ensuring that they remain at the forefront of vaccine technology. This concerted focus on innovation and quality allows Walvax not only to address the existing public health challenges but also to anticipate future needs. Financially, Walvax operates through a well-oiled revenue model primarily driven by its sales of vaccines to both domestic and international markets. The company has crafted a streamlined supply chain, ensuring wide accessibility and distribution of its products. Through strategic pricing and partnerships with healthcare providers and government agencies, Walvax ensures steady revenue inflows, enabling continued investment in research and expansion. With China's focus on improving health care infrastructure and rising global awareness regarding the importance of vaccines, Walvax finds itself in an advantageous position. The company's ability to swiftly respond to market demands and regulatory requirements has further solidified its status as a key contributor to public health and a linchpin in the fight against infectious diseases.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Walvax Biotechnology Co Ltd's most recent financial statements, the company has Gross Margin of 81.3%.
You don't have any saved screeners yet
